Jon Hepple is a co-founder of Rosetta. He has more than 15 years’ investment experience in the life sciences industry. Previously, he was at Rothschild Asset Management and British Biotechnology Ltd. He was also a partner at Seroba Life Sciences, where he was on the Boards of Covagen and Opsona. Jon holds a PhD from Cambridge University.
Jon has held Board roles and is actively engaged in portfolio companies such as Catalyst Biosciences, GlycoMimetics, Novimmune, Procertus and Tranzyme, and also has worked closely with GeminX, Polyphor and Zealand. He currently serves on the Boards of Aprea and Clanotech.